

Thu

Docket No.: 20517/0205421-US0

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Jakob FELDING et al.

Application No.: 10/599,121

Filed: June 1, 2007

For: DIPHENYL OX-INDOL-2-ONE COMPOUNDS

AND THEIR USE IN THE TREATMENT OF

**CANCER** 

Confirmation No.: 4503

Art Unit: 1614

Examiner: Mr. James D. Anderson

## RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## Dear Sir/Madam:

In response to the Restriction Requirement set forth in the Office Action mailed May 15, 2009 (Paper No. 20090508), Applicant hereby elects Group I (encompassed by claims 1, 4-8, 21, and 23-29, and new claim 38), with traverse, and the species represented by "6,7-difluoro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one" (on which claims 1, 4-8, 21, 23-25, 28, and 29, and new claim 38 are readable), with traverse, for continued examination.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

## Remarks / Arguments begin on page 29 of this paper.

It is believed that no fees are required for this Response. However, should additional fees be necessary in connection with the filing of this Response, or if a petition for an extension of

Docket No.: 20517/0205421-US0

time is required for timely acceptance of the same, the Commissioner is hereby authorized and requested to charge Deposit Account No. 04-0100 for any such fees, and Applicant hereby petitions for any needed extension of time.

2